Press

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Mar 29 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF / CSE: RVV / FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a…

Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia

Mar 27 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as…

Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting

Mar 27 • 3 min read

Reunion Neuroscience Inc. (NASDAQ: REUN / TSX: REUN), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company’s first-in-human results for lead asset, RE104, have been accepted for a poster presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place on…

Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program

Mar 27 • 4 min read

Numinus Wellness Inc (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy (“PAT”) training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum. The…

FSD Pharma Inc. Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

Mar 24 • 3 min read

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435